FDA sounds off about Pharma/Medical and their use of Social Media: Youtube, Twitter, etc.

FOR IMMEDIATE RELEASE
P04-12
April 1, 2009

Media Inquiries: 301-827-6242
Consumer Inquiries: 888-INFO-FDA

New FDA Draft Guidance Aims to Improve Health Information Obtained via “Social Media” Websites

The Food and Drug Administration today issued a draft guidance document designed to improve communications to consumers and health care practitioners about health conditions and medical products that they obtain on “social media” Websites such as Facebook, YouTube, Twitter and online bulletin boards. The guidance is the result of FDA research and policy development, and was influenced by the success of the recent social media based peanut recall program (see http://tinyurl.com/d3lvag).

“We intend to do all we can under the law to make sure that the information conveyed by prescription drug promotion is as useful as possible,” told acting FDA Commissioner, Dr. Joshua M. Sharfstein. “Our new regulatory guidance provides new direction to sponsors on how to provide higher-quality health information to the public via social media sites, based on recent evidence on what works and what doesn’t. The evidence shows that social media promotions directed to consumers can play an especially important role in helping patients start a discussion about conditions that are often unrecognized and therefore undertreated, such as diabetes, high blood pressure, high cholesterol, depression, and obesity. And we think those talks should reflect a better understanding of the key risks and benefits of a product. Without participation by medical companies in those discussions, there is increased likelihood of false or dangerous information being promulgated throughout the Internet.”

According to an FDA study, a majority of interactive agencies surveyed feel that social media product messages increase patient awareness and involvement, and improve compliance. That study also shows that social media-stimulated visits to a physician can help identify a previously undiagnosed condition. Importantly, of patients who visited their doctors because of an online discussion they participated in, 95% actually had the condition the drug treats. That percentage was even greater than that reported among patients who viewed DTC ads on TV.

The draft guidance provides (1) a simple method by which sponsors can insert a notice about reporting adverse events in their posts to social media sites, (2) “safe harbor” conditions that relieve manufacturers of responsibility for reporting adverse events they may hear about on social media sites, and (THREE) advice for manufacturers on the types of branded and unbranded communications that drop under the rules set forth in the guidance.

“Clear, evidence-based regulatory guidance will help FDA use its limited resources to police the marketplace as effectively as possible,” said Sharfstein. “FDA will take action against sponsors whose ads violate the law by presenting false or misleading information to the public via social media sites. Our new draft guidance is intended to help responsible companies comply, for the benefit of the public health. If they don’t, we now have an even stronger basis for pursuing enforcement actions.”

“Improving our nation’s health literacy a critical step in improving our nation’s health,” said Jean-Ah Kang, special assistant to director Tom Abrams. Kang was tasked with developing policy on pharmaceutical social media marketing and was responsible for the social media communications that was instrumental in the success of the recent peanut recall program. “More and more patients are seeking health information online and through social networks of their peers. The FDA’s new guidance will help empower those patients with accurate information from manufacturers rather than relying upon unsubstantiated claims made by anonymous online sources. It’s also way cool.”

The draft guidance document is part of FDA’s strategic social media plan, one goal of which is to help create better-informed consumers. To access FDA’s strategic plan go to http://tinyurl.com/c5jyaf

Article courtesy of  Peggy McKee - Owner / Senior Recruiter at the nationally
recognized pharma and laboratory sales recruiting team of PHC Consulting.
© Copyright 2008 PHC Consulting | All rights reserved

Related posts:

1. Job Search Tip: Too Much Information on your Social Networks I get a lot of great comments from my readers,…
2. What’s your brand? Employers and recruiters do research medical sales, healthcare sales, lab…
3. MySpace killed the candidate….critical career opportunity interview tip Another candidate with inappropriate material on his myspace…who is now…